Genome-wide DNA methylation data in 12 breast cancer specimens were obtained from six trastuzumab-treated HER2-positive breast cancer patients who experienced recurrence during follow-up (cases) and six individually matched patients who had not developed recurrence and were alive at the date of the case’s recurrence (controls). This evidence concerns the gene ERBB2 and breast cancer.